Stock Expert AI

Content generated by AI editorial engine. Written by Stock Expert AI's research desk with AI assistance. Figures come from FMP data and the official sources cited in the article.

HCA Healthcare, Inc.
HCA - NYSE - $473.19 (as of ) ▼ -1.02%
-
Earnings Tue 26 Jan

HCA opens the
books on Tuesday evening.

The median of 5 price targets is $4851, stock is $473, +2.5% vs the analyst consensus median.

↓ summary below
Quick Take - in 40 seconds ·
C+
Council 2/6 - Historical V1 score 40

C+ — FMP rating1. Form 4: 6 transactions1.

Quick Answer

HCA Healthcare, Inc. (HCA) Q4 consensus: revenue $20.0B1, EPS $8.161. 8 consecutive quarters of beat1.

$8.16 EPS Estimate Last year $8.01 - +2% YoY
8 Beat Streak Expectations beaten consecutively for the last 8 quarters

Q3 FY26 EPS $7.22 vs $6.65 estimate: beat (+8.6%)1. Stock move on the next trading day: +2.9%1.

Next report

What to watch in Q4 FY26 (Jan 26, 2027)

  • EPS: consensus $8.16, against $8.01 in the same quarter a year ago (+2%).
  • Revenue: consensus $20.0B.

Watchlist

6 metrics stand out this quarter.

3% Investor Focus

Q3 Volume Growth

Same-facility adjusted admissions grew 3% in Q3, accelerating from 2.3% year to date.

Samuel N. Hazen, CEO - Q3 FY26 Earnings Call - October 27, 2026
2026 Expectation / Guide

Fy2026 Guidance Upper Half

HCA reaffirmed its 2026 guidance ranges and expects to finish in the upper half of them.

Michael A. Marks, CFO - Q3 FY26 Earnings Call - October 27, 2026
$550 million Investor Focus

Medicaid Supplemental Headwind 2027

HCA expects $550 million to $650 million less in Medicaid supplemental payment net benefits in 2027.

Samuel N. Hazen, CEO - Q3 FY26 Earnings Call - October 27, 2026
2027 Expectation / Guide

Fy2027 Early Outlook

Management anticipates 2027 earnings will be generally consistent with 2026.

Samuel N. Hazen, CEO - Q3 FY26 Earnings Call - October 27, 2026
$400 million Investor Focus

Exchange Payer Mix Ebitda Impact

The payer mix shift from exchanges to uninsured reduced adjusted EBITDA by approximately $400 million in Q3.

Michael A. Marks, CFO - Q3 FY26 Earnings Call - October 27, 2026
Medicaid Investor Focus

Cost Discipline

Same-facility cost per equivalent admission, excluding Medicaid supplemental payments, was essentially flat versus the prior year quarter.

Michael A. Marks, CFO - Q3 FY26 Earnings Call - October 27, 2026

Stock Expert AI - Methodology

Do our scoring pillars, 6 perspectives, and Munger lens point in the same direction?

Council Score 2 / 6 Bullish

6 investor frameworks. 2 bullish (Ray Dalio, Ken Griffin), 0 bearish (none), 4 neutral (Jim Simons, Klarman, Buffett, Munger).

How is it calculated? ->
Ray Dalio macro - target upside +2.5%
Ken Griffin flow - 50d MA above
Jim Simons quant - RSI 61
Klarman value - target upside +2.5%
Buffett quality - ROE score 1/5
Munger valuation - target upside +2.5%
Munger's Mindset character & balance sheet lens
Fairly Valued

Quality business, trading at fair value.

How is it calculated? ->
Financial HealthWeak
Margin of SafetyWeak
Interest CoverageAdequate
ROIC vs WACCTight
Technical Levels - Pre-earnings positioning

What levels is the stock being tested at?

RSI(14)
60.7 RSI 60.7 positive momentum, 50d above
MACD
+8.20 price above 50d - support positive
50d MA
$437 stock 8.2% above - short-term support
200d MA
$444 stock 6.5% above - long-term support
Volume (10d)
-21% decrease - low participation
Resistance
$485
Analyst median target - upgrade trigger if broken
Current
$473
Pre-earnings position
Support
$378
Invalidation - close below this is a technical breakdown
Pattern
Range
$378-$485 band - earnings breakout/breakdown trigger

Past Performance

4 quarters shown.

BEAT
Q4 FY25
$8.01 vs $7.46 est · Next-day price move: -2.9%
BEAT
Q1 FY26
$7.15 vs $7.12 est · Next-day price move: +3.1%
BEAT
Q2 FY26
$7.59 vs $7.56 est · Next-day price move: +1.9%
BEAT
Q3 FY26
$7.22 vs $6.65 est · Next-day price move: +2.9%

Three scenarios: what could happen?

EPS < $7.92 (no guidance)

Michael A. Marks].

"First, we expect demand for services to remain strong with volume growth forecasted to be 2% to 3%."

- Michael A. Marks, CFO - Q3 FY26 Earnings Call - October 27, 2026
Backlog concentration

No RPO/backlog concentration disclosed in Q3 earnings call.

Insider trading signal

Form 4 Q3 FY26: 6 transactions, net -$16.96M1.

Executive Action Amount Date
McAlevey Michael R EVP & Chief Legal & Admin Off. Sale -$903.5K 2026-02-18
Wyatt Christopher F. SVP & Controller Sale -$2.02M 2026-02-12
Berres Jennifer SVP & Chief Human Res. Officer Sale -$2.02M 2026-02-12
Berres Jennifer SVP & Chief Human Res. Officer Sale -$2.11M 2026-02-12
HAZEN SAMUEL N director, CEO Sale -$7.40M 2026-02-05
HAZEN SAMUEL N director, CEO Sale -$2.51M 2026-02-05

6 transactions · 6 sales / 0 purchases = net negative flow. Not large in absolute terms against a $102.4B market cap.

CapEx shock

Q3 CapEx $1.4B1. Q3 op margin 14.9%1 - this level in Q4 is sensitive to CapEx revision risk.

"Capital expenditures totaled approximately $1.36 billion in the quarter."

- Michael A. Marks, CFO - Q3 FY26 Earnings Call - October 27, 2026
Framework - Position discipline

After the data arrives: 3 scenarios, 3 windows

Not advice - a structural framework for earnings night. Decision discipline is yours.

Scenario A - Beat
Q4 EPS > $8.16 + CapEx discipline
Threshold: EPS > $8.161.
Target: Break above median target $4851; high target $5791 upper bound.
Scenario B - In-Line
EPS approx $8.16 + CapEx < $1.4B
Threshold: EPS approx $8.161, Q4 CapEx < $1.4B1.
Target: Consolidation in the band between current $4731 and median $4851.
Scenario C - Miss
EPS < $7.92 or CapEx >= $1.4B
Threshold: EPS < $7.921.
Current price $473 — above SMA200 $4441.

Market Outlook

What do analysts say? 5 price targets · 27 ratings

Wall Street Consensus
$485
12-month median target price (+2.5% gap to the analyst consensus median)
15
BUY
10
HOLD
2
SELL
Risk Management
$378
Invalidation level - critical support threshold
$437 - 50-day MA (above, +8.2%)
$444 - 200-day MA (above, +6.5%)
IV Crush risk (sudden drop in inflated option premiums before earnings): Option premiums are inflated before earnings.
Verdict - HCA Q4 FY26
C+

You read it in 5 minutes. When the numbers come out on Tuesday evening - you know what you're looking at.

Data arrives at night. The framework is ready now.

Data arrives on Tuesday evening. The framework is ready on this page: Q4 EPS threshold $8.161, CapEx threshold "below $1.4B". Two anchors, three scenarios.

Comparison Stock Expert AI is free today — no credit card.

3 subscriptions. 1 platform.

Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts

Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing

Stock Expert AI is free today — no credit card. Council 6-lens analysis + MoonshotScore multi-pillar + Insider tracker + Technical levels - all in one platform, for every stock.

Educational tool, not investment advice. Past performance does not guarantee future results.

Calendar

Catalyst Calendar - 90-day forward look

Jan 26, 2027EARNINGSQ4 FY26 results (after market close) + earnings call
Jan 27, 2027PRICEFirst trading day after earnings - 200dMA test + IV crush
Mar 1, 2027 – Mar 31, 2027FILING10-K due within 60–90 days of fiscal year end (by Mar 1, 2027 – Mar 31, 2027); the exact deadline depends on filer status
~Apr 28, 2027EARNINGSQ1 FY27 (next quarter, date not yet scheduled in FMP)

DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.

Frequently Asked Questions

What does the HCA Q4 FY26 earnings preview cover?

This HCA Healthcare, Inc. (HCA) Q4 FY26 earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.

What should investors watch for in HCA Q4 FY26 earnings?

HCA Healthcare, Inc. (HCA): Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.

Where do the numbers on this page come from?

HCA Healthcare, Inc. (HCA): Figures are sourced from Financial Modeling Prep (FMP) fundamentals and consensus data plus official earnings-call transcripts; derived metrics are labeled with their source next to each figure.

Is this a buy or sell recommendation?

HCA Healthcare, Inc. (HCA): No. This page is educational research, not investment advice. It summarizes analyst consensus and company data; consult a licensed financial advisor before making any investment decision.

More earnings, decoded